This authorization from the Central Drugs Standard Control Organization (CDSCO) marks the introduction of this treatment as a ...

The head of the pharmaceutical giant warns that Europe's decline in manufacturing innovative medicines is likely to accelerate as a result of the policies pursued by Donald Trump. According to Soriot, ...

Ola Electric: Promoter Bhavish Aggarwal could sell additional shares in open market to bring down stake to 34-35% from 36.78% as of September ended quarter, sources told NDTV Profit. Post this, there ...

AbbVie and several other drugmakers are expected to announce on Friday agreements with the U.S. government to lower certain ...

The White House is set to announce drug pricing deals with pharmaceutical heavyweights Novartis AG and Roche Holding AG as ...

In this video, Matthew S. Davids, MD, spoke about the BRUIN-314 trial, one of the first head-to-head studies to compare pirtobrutinib, a noncovalent Bruton tyrosine kinase inhibitor, with ibrutinib, a ...

Combining elacestrant with targeted agents produced “clinically meaningful” outcomes for patients with locally advanced or metastatic ER-positive/HER2-negative breast cancer who have received at least ...

Earlier this year, Australia rolled out its newest screening program in 20 years, but can it reach those most at risk?

As of midyear, Maryland’s biomanufacturing footprint had a 1.1% vacancy rate, while its R&D footprint sat at 10.8% vacant, ...

Exploration of key clinical trial data and real-world evidence on dupilumab in asthma and COPD presented at the ERS and CHEST ...

The approval could help Enhertu, which is already a multibillion-dollar seller, supplant a regimen that’s been the standard ...

FDA approval moves trastuzumab deruxtecan in combination with pertuzumab into frontline treatment of unresectable or ...